Payment overview · 2025
General Payments
$1,587.64
64 reported records · 11 companies
Healthcare provider profile · identity verified
Angela Eakels, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ORLANDO, FL · NPI 1659863843
Verified facts
What the public records show
CMS Open Payments records show Angela Eakels, APN received $1,587.64 in general payments during 2025 across 64 reported records.
ViiV Healthcare Company accounted for 61.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Dovato, Pifeltro, Rukobia.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Descovy by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DELSTRIGO as an associated drug or biological on 864 records involving 608 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Delstrigo by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GARDASIL 9 as an associated drug or biological on 35573 records involving 25304 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gardasil 9 by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Pifeltro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $970.64 | 61.1% | 39 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $238.25 | 15.0% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $90.68 | 5.7% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $87.21 | 5.5% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.42 | 2.9% | 2 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $44.78 | 2.8% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $41.36 | 2.6% | 2 | 2025 |
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.34 | 1.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.05 | 1.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.54 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.37 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,587.64 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $518.28 | 19 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $248.61 | 10 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $205.30 | 11 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $90.68 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.42 | 2 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $41.36 | 2 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $41.36 | 2 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $34.45 | 1 | 2025 |
Source payment records
|
|||||
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 13 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 105 | exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RUKOBIA rukobia |
2025 | Rukobia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
240 | 37 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | DELSTRIGO open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 608 recipient NPIs · example record 1237993240 |
Delstrigo · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | GARDASIL 9 open payments reported associated product |
CMS Open Payments — General Payments 35573 supporting records · 25304 recipient NPIs · example record 1237992212 |
Gardasil 9 · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
105 | 15 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 240 | 37 |
| Dovato | Dolutegravir Sodium/Lamivudine | 105 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 74 | 15 |
| Tivicay | Dolutegravir Sodium | 67 | 11 |
| Prezcobix | Darunavir/Cobicistat | 46 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 43 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 40 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 37 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 30 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 29 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Lisinopril | Lisinopril | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | 15 | suppressed |
| Losartan Potassium | Losartan Potassium | 15 | suppressed |
| Pifeltro | Doravirine | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Atovaquone | Atovaquone | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Gardasil 9 | Hpv Vaccine 9-Valent/Pf | 12 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 11 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,587.64 · 64 records | ViiV Healthcare Company | ABRYSVO, ACCRUFER, APRETUDE, APTIMA, CABENUVA, COMIRNATY, Cologuard Collection Kit, DOVATO, EGRIFTA, MOUNJARO, Mytesi, PIFELTRO, PREVNAR 20, RUKOBIA, THINPREP 2000 PROCESSOR, TROGARZO, Yeztugo, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error